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ABSTRACT
While small interfering RNAs (siRNAs) have been
rapidly appreciated to silence genes, efficient and
non-toxic vectors for primary cells and for systemic
in vivo delivery are lacking. Several siRNA-delivery
vehicles, including cell-penetrating peptides
(CPPs), have been developed but their utility is
often restricted by entrapment following endocyto-
sis. Hence, developing CPPs that promote endo-
somal escape is a prerequisite for successful
siRNA implementation. We here present a novel
CPP, PepFect 6 (PF6), comprising the previously
reported stearyl-TP10 peptide, having pH titratable
trifluoromethylquinoline moieties covalently incor-
porated to facilitate endosomal release. Stable PF6/
siRNA nanoparticles enter entire cell populations
and rapidly promote endosomal escape, resulting
in robust RNAi responses in various cell types
(including primary cells), with minimal associated
transcriptomic or proteomic changes. Furthermore,
PF6-mediated delivery is independent of cell conflu-
ence and, in most cases, not significantly hampered
by serum proteins. Finally, these nanoparticles
promote strong RNAi responses in different organs
following systemic delivery in mice without any
associated toxicity. Strikingly, similar knockdown in
liver is achieved by PF6/siRNA nanoparticles and
siRNA injected by hydrodynamic infusion, a golden
standard technique for liver transfection. These
results imply that the peptide, in addition to having
utility for RNAi screens in vitro, displays therapeutic
potential.
INTRODUCTION
Since the discovery of siRNAs, a key mediator of RNA
interference (RNAi), an ever increasing number of publi-
cations has afﬁrmed their utility in inducing gene silencing
(1–4). Not only have siRNAs been exploited in target val-
idation studies but the technology has also raised tremen-
dous attention as a potential therapeutic platform (2).
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ploited for studying gene function and to identify new
disease targets. However, while it is possible to design
siRNA libraries to target entire genomes, the applicability
of large high throughput screens in mammalian cells is
limited due to problems in siRNA delivery, especially
into primary- and suspension cells. The anionic nature
and large size of siRNAs unfortunately imply that the
cell membrane constitutes an impermeable barrier.
Numerous delivery systems have therefore been developed
to increase cellular internalization and tissue distribution
of siRNAs (3,4). Unfortunately most transfection
strategies fail to fulﬁll the criteria of an optimal delivery
system, namely to: transfect entire cell populations inde-
pendent of cell type and conﬂuence, be active in the
presence of serum proteins, display minimal toxicity, and
work systemically in vivo. Thus, universal, robust, simple
and effective in vitro delivery methods must be developed
before harnessing the beneﬁts from large-scale RNAi
screens.
Cell-penetrating peptides (CPPs) have the earmarks of
promising delivery vectors since they enter entire cell popu-
lations in a non-toxic fashion (5,6). These relatively short
cationic peptides have been used in various settings for
conveying different types of macromolecules. As a result
of the synthetic origin of most CPPs, they can be designed
to have predetermined structures, and as an additional im-
plication of their synthetic nature, CPPs can easily be
modiﬁed with different chemical entities. To further
widen their applicability, CPPs can be recombinantly ex-
pressed together with speciﬁc proteins or be used in com-
bination with other delivery systems. Taken together, this
opens the door to a myriad of possibilities to rationally
design peptide-based delivery vehicles.
There are several reports on successful siRNA delivery
in vivo by using e.g. cholesterol-functionalized siRNAs,
lipid-based nanoparticles etc., some of which are being
evaluated in clinical trials (7). Nevertheless, all these for-
mulations have their limitations, e.g. activation of toll-like
receptors (TLRs), delivery is restricted almost exclusively
to the liver, tissue toxicity, to name a few. CPPs could
theoretically offer several advantages over other available
vectors, however, only a handful of publications have
reported on CPP-assisted siRNA delivery (8). Some suc-
cessful attempts have been made to design structurally
well-deﬁned CPPs for siRNA delivery, both in vitro and
in vivo. For instance, the MPG-8 peptide has been used
in vivo for intratumoral (i.t.) injections and cholesterol-
modiﬁed MPG-8 for systemic delivery (9). Also,
CPP-functionalized multifunctional envelope-type nano
device (MEND) formulations have been used for i.t. and
ex vivo siRNA delivery (10,11). While these CPP-based
delivery systems rely on interactions between siRNAs
and CPPs to form nanoparticles, other strategies have
been exploited as well. Dowdy and colleagues approached
the siRNA delivery-associated problems from a different
angle. They used a CPP recombinantly expressed as a
fusion protein with a double-stranded RNA binding
domain (named Tat-DRBD), thereby masking the
anionic nature of siRNAs (12). Although this system efﬁ-
ciently transfected siRNAs into primary cells in a
non-toxic manner, transfection media devoid of negative
glycosaminoglycans (GAGs) was generally required.
Possibly for this reason, no systemic in vivo delivery data
has yet been reported for this system (13). Albeit
promising attempts for siRNA delivery have been made,
there is still plenty of room for improvements in rational
design of CPP-based vectors.
In light of the above, we set out to design a CPP-based
siRNA-delivery system that could be robustly synthesized,
easy to use and endowed with the desired delivery
properties. Due to the negative charge of siRNAs and
the cationic nature of CPPs, it is very cumbersome to
generate covalent conjugates. However, it has been previ-
ously reported that CPPs with certain properties can be
non-covalently complexed with siRNAs and be used
in vitro (9,14) or, for targeted delivery, in vivo (15,16).
Although this approach has worked in some laboratories,
most CPPs fail to deliver siRNAs using this strategy
(6,17). The likely explanation is that the complexes
are retained intracellularly, inside endosomes following
endocytosis (8). We hypothesized that by covalently
introducing a potent proton-accepting moiety, i.e. a
novel chloroquine analog (18) into a CPP (i.e. TP10), it
would be possible to facilitate escape from acidic endo-
somal compartments by osmotic swelling and by delaying
the acidiﬁcation of the endosomes and, thereby, delaying
the lysosomal degradation pathway. Furthermore, based
on prior experience that stearylation improves the activity
of TP10 in serum (19), a stearyl moiety was introduced,
generating the PepFect 6 (PF6) peptide. TP10 was chosen
in this study since it has been previously used successfully
both in vitro and in vivo (20) for nucleic acid delivery.
Furthermore, introduction of the above-mentioned
chemical modiﬁcations in any other tested CPP had
negligible effects on siRNA-delivery (data not shown).
The rationally designed PF6 peptide promoted signiﬁ-
cant siRNA-mediated RNAi responses in vitro, even in
various refractory cells, and, perhaps most importantly, it
facilitated signiﬁcant siRNA-mediated gene knockdown in
several tissues following systemic administration in mice. It
should be stressed that these effects were achieved by using
a single-component delivery system, without exploiting
targeting ligands and without requiring PEGylation of
the PF6/siRNA nanoparticles. Judging by these properties,
the PF6 technology could overcome several limitations of
many currently used siRNA delivery systems.
MATERIALS AND METHODS
Synthesis of the triﬂuoromethylquinoline derivative
4-Chloro-7-(triﬂuoromethyl) quinoline (3.8g, 16.4mmol)
and N-methyl-2,20-diaminodiethylamine (25ml,
194.1mmol) was heated (80 C, 2.5h; 130 C, 3h; 140 C,
2.5h). After cooling to RT, cold DCM was added, the
precipitate was ﬁltered off and discarded. The organic
phase was washed (5% NaHCO3 aq 2, H2O 2) and
dried [MgSO4(s)], and the solvent was removed under
reduced pressure giving the N-(2-aminoethyl)-N-methyl-
N0-[7-(triﬂuoromethyl)-quinolin-4-yl]ethane-1,2-diamine
(QN) (4.5g, 14.4mmol, 83%, calculated mass: 312.3 Da,
Nucleic Acids Research,2011, Vol.39, No. 9 3973found: 312.1 Da (Perkin-Elmer prOTOF
TM 2000 O-TOF
MALDI instrument). Crude product (>90% purity ac-
cording to HPLC) was used without further puriﬁcation.
TP10 synthesis
This was performed on a SYRO multiple peptide synthe-
sizer (MultiSynTech GmbH) using a polystyrene-based
Rink amide resin (0.4–0.6mmol/g). Standard
7 Fmoc
(9H-ﬂuoren-9-ylmethoxycarbonyl)-AA-OH [except Lys
7,
Fmoc-Lys(Mtt)-OH] were coupled using HBTU (3 eq.,
O-benzotriazole-N, N, N0, N0-tetramethyl-uronium-
hexaﬂuorophosphate) as activating reagent and DIEA
(6 eq., diisopropylethyl amine) as base.
Synthesis of PF6
Resin-bound TP10 [Fmoc-AGYLLGK(e-Mtt)INLKA
LAALAKKIL- Rink amide resin] was manually treated
to generate the N-terminal free amine (35% piperidine,
40min) followed by coupling of stearic acid, BOP
[benzotriazol-1-yloxytris(dimethylamino)-phosphonium
hexaﬂuorophosphate] and DIEA in DCM for 1h. To the
e-amino group of Lys
7 (deprotected by repeated washes of
1% TFA, 3–4% TIS in DCM 1–1.5h), Fmoc-Lys(Fmoc)-
OH (3–5 eq.) was coupled as HOAt (1-hydroxy-
7-azabenzotriazole) ester. After Fmoc removal (35%
piperidine, 40min), repeated coupling and ﬁnal Fmoc
removal resulted in a lysine tree containing four free
amino groups. These were treated with succinic anhydride
(1.5 eq.) and DIEA (3 eq.) in DMF (dimethyl formamide)
for 10min. QN (2.5 eq. in DMF) was coupled over night
to the succinic acid modiﬁed lysine tree [TBTU/HOBt
(3 eq.) and DIEA (6 eq.)]. After cleavage [water/TIS/
TFA 2.5/2.5/95 (v/v)], ﬁltration, precipitation (cold
ether) and drying (lyophilization), crude PF6 was
obtained. PF6 was puriﬁed by RP-HPLC, C18
preparative column (5mm), 45% acetonitrile (ACN)–
water [0.1% TFA], 5min; 45–85% ACN, 60min and
eluted at 80% ACN. After freeze-drying, purity was
>90–95% (HPLC). Product was analyzed
[alpha-cyano-4-hydroxy-cinnamic acid (a-CHCA) as crys-
tallization matrix] by MALDI MS (Perkin-Elmer
prOTOF
TM 2000 O-TOF, positive mode); calculated
mass: 4408.8 Da, found: 4410.4 Da. PF6 will be available
for other scientists for RNAi response validation if
requested.
Synthesis of siRNAs
All siRNAs, synthesized and puriﬁed at GE Healthcare,
Uppsala, were stored at 500mMa t 20 C. Sequences of
siRNAs: EGFP sense 50-GGCUACGUCCAGGAGCGC
ACC and as 50-UGCGCUCCUGGACGUAGCCUU,
Luciferase sense 50-ACGCCAAAAACAUAAAGAAAG
and as 50-UUCUUUAUGUUUUUGGCGUCU, HPRT1
sense 50-GCCAGACUUUGUUGGAUUUGAAATT and
as 50-AAUUUCAAAUCCAACAAAGUCUGGCUU,
Oct4 sense 50-ACUCGAACCACAUCCUUCUU and as
50-GAAGGAUGUGGUUCGAGUUU.
Cell culture conditions
Cells were grown at 37 C, 5% CO2 in humidiﬁed environ-
ment. HEK293, HeLa, U2OS, N2a, SH-SY5Y,
Hepa1c1c7, HepG2, U87, RD4 and primary MEF cells
were grown in 10% FBS-DMEM with glutamax. Bhk21
cells were grown in 10% FBS-GMEM with glutamax sup-
plemented with 0.3% tryptose phosphate broth (Sigma).
THP1, B16, Jurkat and K562 cells were grown in 10%
FBS-RPMI-1640 media. All cells were supplemented
with 0.1mM non-essential amino acids (NEAA), 1.0mM
sodium pyruvate and antibiotics (100 U/ml penicillin and
100mg/ml streptomycin). These chemicals were purchased
from (Invitrogen, Sweden). HUVECs were grown on
gelatinized cell culture plates in Endothelial Cell Growth
Medium 2 supplemented with SupplementMix C39216
(PromoCell). C17.2 cells were grown in 10% FCS-
DMEM High Glucose (4.5g/l) with L-glutamine, 5%
horse serum and 20mg/ml gentamycin. mES cells were
grown in DMEM high glucose (4.5g/l) with L-glutamine,
0.1mM NNEA, 1.0mM sodium pyruvate, 15% ES-cell
tested FBS, antibiotics, 0.1mM 2-mercaptoethanol and
1000U/ml leukemia inhibitory factor, using mitomycin
C inactivated mouse embryonic ﬁbroblasts as feeder
monolayer. Luciferase stable cells were generated by
lipofection of pGL3 luciferase plasmid (Clontech) under
selection with Hygromycin (Sigma). Luc-HepG2 cells were
generated by lentiviral transduction. EGFP-CHO cells
were provided by Andres Merits.
Formulation, characterization and treatment with PF6/
siRNA
PF6 (100mM stock solution) was mixed with siRNA
(10mM stock solution) in MQ water in one-tenth of ﬁnal
treatment volume (i.e. 50ml), using MR30 in serum free
media or MR40 in serum experiments. Complexes were
formed for 30min at RT and added to cells, grown to
60% conﬂuence in 24-well plate, in 450ml growth media.
After 4h, 1ml of fresh media was added to wells and cells
were incubated for indicated times. Treatments with
LF2000 and RNAiMAX were conducted in accordance
with recommendations from manufacturer (Invitrogen),
using 1ml/well for 50nM siRNA in 24-well plates.
Transductin
TM was used according to guidelines (IDT
Technologies), using 6–7mM reagent with 100nM
siRNA but performing experiments in serum supple-
mented or serum free media (instead of Q-serum devoid
of GAGs). In luciferase experiments, cells were lysed using
100ml of 0.1% Triton X-100 in Hepes Krebbs Ringer
buffer. After 30min lysis on ice, luciferase expression
was measured using Promega Luciferase Kit on 96-well
Glomax luminometer (Promega). If using Cy5-labled
siRNAs, lysates were ﬁrst analyzed by ﬂuorometry using
a Spectra Max Gemini (Molecular Devices) prior to
luciferase measurements. For in vivo treatment trials,
PF6/siRNA particles (MR30) were formed in MQ-water
in half of the injection volume (i.e. 100ml), using 2mM
PF6 and 0.5mM siRNA stock solutions. After 30min in-
cubation, 100ml of 10% glucose or 10.8% mannitol
solution was added to the particles. Two hundred micro
liter solution was injected into the tail-vein of mice.
3974 Nucleic Acids Research, 2011,Vol.39, No. 9Hydrodynamic infusions in tail vein of mice were carried
out using 1mg/kg siRNA in 2ml saline buffer injected
with high pressure. Hydrodynamic mean diameter of
PF6/siRNA particles was determined (using a refractive
index of 1.338) by DLS studies (Zetasizer Nano ZS appar-
atus, Malvern Instruments) and z-potential was measured
using the same instrument.
Liposome leakage assay
Large unilamellar vesicles (LUV) were prepared by mixing
dioleoylphosphatidylcholine (DOPC)/
dioleoyl-phosphatidylethanolamine (DOPE)/phosphati-
dylinositol (PI)/bis (monooleoylglycero) phosphate
(LBPA) (Avanti polar lipids) (DOPC/DOPE/PI/LBPA:
5/2/1/2) and 10mmol of the mixture in organic solvent
(chloroform/ethanol: 9/1) was dried by evaporation
under nitrogen atmosphere and rehydrated using 1ml of
20mM MES buffer containing 12.5mM ANTS ﬂuoro-
chrome (8-aminonaphthalene-1,3,6-trisulfonic acid),
disodium salt (Invitrogen), 45mM DPX quencher
(p-xylene-bispyridinium bromide) (Invitrogen) and
75mM NaCl, pH 5.5. The lipid suspension was agitated
on a vortex and submitted to ﬁve cycles of freeze/thawing
before passage 21 times through 100nm polycarbonate
ﬁlter (Nucleopore, Whatman) using a mini extruder
(Avanti polar lipids). Free dye and quencher were
removed by gel ﬁltration on a Sephadex G-50 column
(Amersham Biosciences). Liposomes were eluted with
20mM MES buffer, 145mM NaCl, pH 5.5 and analyzed
on a submicron particle size analyzer (Coulter N4,
Beckman). Phosphatidylcholine was quantiﬁed using a
LabAssay phospholipids kit (Wako) according to manu-
facturer’s instructions. Liposomal leakage was measured
on a luminescence spectrometer (Perkin Elmer LS 55) at
pH 5.5 or 7.4.
Flow cytometry analysis and ﬂuorescence microscopy
For FACS analysis, 6 10
4 cells/well were seeded onto
24-well plates one day before experiment. After treatment,
cells were washed with PBS, trypsinized, resuspended in
ice-cold PBS containing 2% FBS and analyzed on a BD
LSRII ﬂow cytometer (BD Biosciences) using FacsDiva
software (BD Biosciences). For microscopy, 2   10
4
cells/well were seeded into Lab-Tek
TM 8-chambered
cover glasses (Nunc; Thermo Fisher Scientiﬁc) 24h
before experiment. After treatment cells were washed
with PBS, stained with trypan blue and imaged on
Nikon Eclipse TE2000-U inverted microscope.
Immunocytochemistry
mES cells grown on gelatinized cover slips placed in
24-well plates using inactivated MEFs as feeder mono-
layer were transfected as described above. After 72h,
cells were ﬁxed with 4% paraformaldehyde in PBS
(15min), permeabilized (2 15min) with 0.25% Triton
X-100 solution in PBS (PBST) and blocked with 5%
normal goat serum (NGS). Cells were treated with
0.8mg/ml rabbit polyclonal primary antibody to Oct4
(ABCAM) in solution of 2% NGS, in PBST for 1h at
RT, and washed 3 10min with PBST. Secondary goat
antirabbit Alexa-568 (2mg/ml) antibody (Invitrogen) in
solution of 2% NGS in PBST was incubated for 1h at
RT, and cells were washed 2 10min with PBST supple-
mented with 0.5mg/ml DAPI to stain the nuclei.
Coverslips were mounted on glass slides using 30%
glycerol in PBS. Cells were imaged using Nikon Eclipse
TE2000-U inverted microscope.
RNA extraction and qPCR analysis
RNA from cultured cells and tissue samples was extracted
using NucleoSpin RNA II Puriﬁcation Kit (Macherey and
Nagel) or TRIzol Reagent (Invitrogen), respectively.
cDNA was synthesized with First Strand cDNA
Synthesis Kit (Fermentas), HPRT1 mRNA expression
was detected using 5 HOT FIREPol EvaGreen
qPCR Mix Plus (ROX) (Solis BioDyne) on 7900HT
Real-Time PCR System (Applied Biosystems). HPRT1
mRNA expression was normalized against internal
standard GAPDH.
Cell viability assay
Ten thousand cells/well were seeded in 96-well plates and
treated with 100nM siRNA together with transfection
reagents as indicated. The Wst-1 assay was used to assess
metabolic activity after 24h according to manufacturer’s
protocol (Roche) using a Tecan spectrophotometer.
Microarray analysis
RNA was ampliﬁed and biotinylated using the Illumina
TotalPrep RNA Ampliﬁcation Kit (Ambion, Applied
Biosystems) and puriﬁed, fragmented and hybridized to
Illumina Human-6 V2 & V3 BeadChip arrays (Illumina).
Background subtraction, expression summary, normaliza-
tion, log base 2 transformation and MA-plots were carried
out using R (Bioconductor).
Mass spectrometry-based proteomics analysis
Cell lysates were treated with DTT/iodoacetamide and
trypsinized overnight. Samples were labeled with iTRAQ
8plex (Applied Biosystems) and separated by immobilized
pH gradient—isoelectric focusing (IPG-IEF) on a narrow
range strip (GE Healthcare) (21). Extracted fractions from
the IPG-IEF were separated using a nano-LC system
(Agilent1200) coupled to LTQ Orbitrap Velos MS
(Thermo Scientiﬁc). Proteome discoverer 1.1 with
Mascot 2.2 (Matrix Science) was used for protein identi-
ﬁcation searching IPI database (3.64), limited to a false
discovery rate of <1% and  2 peptides/protein.
IL-1b, TNF-a and IL-6 analysis
THP1 cells were differentiated using phorbol myristate
acetate (PMA) (10ng/ml) for 48h before experiment and
seeded onto 24-well plate (2 10
5 cells/well). Cells were
treated as previously. LPS (15mg/ml) was used as
positive control. Culture supernatants were collected at 4
and 24h after treatment, and assayed for IL-1b and
TNF-a by ELISA according to manufacturer’s protocol
(R & D systems). IL-6 and TNF-a levels in blood were
analyzed at 24h post i.v. injection of NMRI female mice
Nucleic Acids Research,2011, Vol.39, No. 9 3975with 1mg/kg PF6/siRNA, siRNA only, vehicle only (5%
glucose) or LPS (10mg). Blood was collected retro-
orbitally and serum was puriﬁed using serum separation
tubes (BD Bioscience). Serum (100ml) was assayed using
ELISA Max Deluxe Set (Biolegend) and absorbance
measured on Spectra Max (Molecular Devices).
RNAi experiments in vivo
In HPRT1 experiments, C57Bl/6JOlaHsd (Harlan)
females were utilized for treatments. Animals were
randomized into four groups (n=3–6) and treated as
indicated. At 24 or 72h, mice were sacriﬁced by cervical
dislocation and tissues collected and rapidly frozen in
liquid nitrogen (except for blood that was collected into
heparinized tubes and stored at 4 C). Blood sample
analysis of white blood cell count and levels of s-CRP
was conducted by the United Laboratories at Tartu
University Hospital. Clinical chemistry parameters
(ALT/AST and creatinine levels) on serum from NMRI
female mice, prepared as previously described, were
analyzed after 72h treatments by the Clinical chemistry
laboratory at Karolinska University Hospital using IFCC
standardized techniques. Lung, liver and kidney were
dissected after 72h and ﬁxed in formalin, embedded in
parafﬁn and stained with hematoxylin. Histology
sections were analyzed by the Pathology department at
Karolinska University Hospital. In luciferase experiments,
NMRI adult female mice were injected with a dose of 10mg
UbCeGFPLuc plasmid using hydrodynamic technique
(ref.). After 3 weeks, D-luciferin (150mg/kg) was injected
intraperitoneally and following 4min incubation, bio-
luminescence imaging was performed in a Xenogen
IVIS100 imager (Xenogen) using 5min exposure and
high-sensitivity setting. Mice were imaged in a ventral pres-
entationtomonitorliver-expressionandquantiﬁedbytotal
ﬂuxusing Living Image Software (Xenogen). Animals were
then randomized into four groups (n=4 in each group)
and treated as indicated and assayed at Day 3, 5, etc.
During experiment, animals were anesthetized using 4%
isoﬂurane. Experiments were approved by the Swedish
local board for laboratory animals.
Statistical analysis
Results are presented as mean±SEM. Statistical signiﬁ-
cance (*P<0.05, **P<0.01 and ***P<0.001) was
calculated using one-way ANOVA with Tukey multiple
comparison test.
RESULTS
Design of PF6
We aimed to develop a peptide-based carrier for siRNA
delivery by introducing modiﬁcations into the well-
characterized TP10 peptide (Figure 1a, compound 1).
Successful carrier development necessitates solving two
often occurring issues: (i) because the RNAi machinery
resides in the cytoplasm of cells, it must be ensured that
CPP/siRNA complexes, which are taken up by cells via
endocytic pathways, are as promptly as possible released
into the cytoplasm; and (ii) the CPP/siRNA complexes
must be protected from being degraded in serum.
It is known that co-addition of the lysosomotropic
agent chloroquine (CQ) in solution enhances endosomal
release of peptide-based delivery vehicles. Therefore it was
reasonable to assume that TP10, containing covalently
attached CQ analogs (Figure 1a, compound 2), would
more efﬁciently deliver siRNA into the cytoplasm and
would also allow ﬁne tuning of the overall in vitro concen-
tration of these proton accepting moieties by changing the
number of covalently attached CQ analogs. In contrast to
CQ added in solution, a covalently attached CQ analog
would exhibit an effective concentration only locally
inside the endosomes. Also, we have previously shown
that both the delivery efﬁciency and stability of TP10
are enhanced when the peptide is N-terminally stearylated
(19) [Figure 1a, compound 3, PepFect 3 (PF3)]. Hence we
hypothesized that TP10, containing both the fatty acid
modiﬁcation and a CQ analog, would have the required
properties for siRNA delivery.
As previously reported (18), exchanging the quinoline-
substituted 7-chlorine to a lipophilic triﬂuoromethyl
group resulted in a signiﬁcant increase in endosomolytic
activity of the CQ analog. However, the number of carbon
atoms between the two amines in the side-chain of the CQ
analogs was of less importance. Furthermore, increasing
the number of amines in the side chain from two to four
gave only a slight increase in activity. Based on these data,
we monoarylated one of the primary amines in
N-methyl-2,20-diaminoethylamine with 4-chloro-7-
(triﬂuoromethyl)quinoline, which gave a suitable deriva-
tive (QN) that could be further attached to TP10 via a
dicarboxylic acid linker, i.e. succinic acid. As previously
reported (20) the side chain of Lys
7 residue of TP10 was
found to be the preferred site for modiﬁcations. First, one
succinylated QN was attached to the side-chain of Lys
7
(Figure 1a, compound 4), which resulted in slightly
increased activity of the TP10 peptide (data not shown).
We then hypothesized that by introducing several QN mol-
ecules, the effect would increase further. Incorporation of a
lysine tree to the Lys
7 residue of TP10, followed by
succinylation and covalent attachment of four QN mol-
ecules to the lysine tree, gave rise to the PF5 peptide
(Figure 1a, compound 5). PF5 indeed promoted efﬁcient
siRNA-mediated RNAi responses in cell culture but, un-
fortunately, these effects were severely reduced in the
presence of serum proteins (data not shown). Since we
have previously shown that the delivery efﬁciency and sta-
bility of TP10 is enhanced when the peptide is N-terminally
stearylated, we introduced both the QN and fatty acid
modiﬁcations in order to increase the performance of the
siRNA delivery vehicle in complete cell growth media,
generating the PF6 peptide (Figure 1a, compound 6).
Characterization and evaluation of the endosomolytic
design of PF6
To assess whether PF6 can form nanoparticles with
siRNA, the peptide was co-incubated with siRNA in
water at different molar ratios (MRs) ranging from 0–40
of peptide over siRNA and the size of particles was
3976 Nucleic Acids Research, 2011,Vol.39, No. 9analyzed over time by dynamic light scattering (DLS). At
all MRs, PF6 formed homogenous, unimodal nano-
particles with siRNA having particle sizes of 70–100nm,
which remained stable at 4 C for at least 4 weeks both in
water with or without mannitol or glucose (Figure 1b and
Supplementary Table S1). The presence of serum proteins
generated a population of larger particles (125–200nm)
with wider distribution but, importantly, the population
was intact for at least 1h (Figure 1b). At all tested ratios in
serum media, PF6/siRNA particles displayed a slightly
negative surface charge, with zeta-potentials ranging
from  7t o 11mV.
To validate the endosomolytic properties of PF6, we ini-
tially assessed the potency of the peptide to promote
endosomal escape of siRNA. As seen in Figure 1c,
alreadyafter1hPF6/Cy5-labeledsiRNAwasendocytosed,
judging by the extensive vesicular distribution. In order to
estimate the degree of endosomal release conferred by the
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Figure 1. Rational iterative design and general properties of PF6. (a) Chemical structure of the different chemical intermediates of PF6: TP10
backbone (compound 1), succinylated triﬂuoroquinoline based derivative (compound 2), PepFect3 (compound 3), triﬂuoroquinoline based derivative
conjugated to succinylated Lys7 of TP10 (compound 4), PepFect5 (compound 5) and PepFect6 (compound 6). (b) A representative DLS proﬁle on
the distribution of PF6/siRNA particles 30min after formulation in water and at indicated time points after dilution in 10% serum in optiMEM.
(c) Fluorescence microscopy overlay at 1h after treatment of U2OS cells with 50nM PF6/Cy5-siRNA. (d) Uptake (RFU) and RNAi response in
luc-U2OS cells 24h after treatment with 50nM Cy5-labeled luc-siRNA complexed with PF6 or PF3 (left panel). RNAi response after same treat-
ments with- or without co-addition of 100mM chloroquine (right panel). (e) Liposome leakage at different pH after treatment with 50nM PF3/
siRNA or PF6/siRNA.
Nucleic Acids Research,2011, Vol.39, No. 9 3977proton-accepting QN moiety of PF6, it was compared to
PF3, the identical peptide lacking the QN modiﬁcation.
Although both peptides promoted cellular uptake of
Cy5-siRNA to the same extent, only PF6 induced
siRNA-mediated gene silencing (Figure 1d, left panel).
Furthermore, upon co-addition of CQ, PF3/siRNA-
mediated RNAi was signiﬁcantly increased while it had
no impact on PF6/siRNA (Figure 1d, right panel). To
corroborate these ﬁndings, a liposome leakage model was
utilized in which peptide-imparted destabilization of
liposomes at different pH can be assessed. As expected,
PF6-induced liposome leakage was increased substan-
tially when decreasing the pH, while PF3-mediated
destabilization remained unaffected (Figure 1e). These
results clearly illustrate the pH-dependent endosomolytic
properties of PF6.
RNAi responses in reporter cells—PF6 versus lipofection
To date the majority of siRNA-transfections are carried
out using cationic liposomes, such as Lipofectamine
TM
2000 (LF2000). Thus, PF6 was compared to LF2000 in
dose-response experiments using luciferase (luc)-stable
human embryonal kidney (HEK) and human osteosar-
coma (U2OS) cells. Not only did PF6 confer siRNA-
mediated gene silencing dose-dependently, but more
importantly, the response was relatively well-preserved in
serum and signiﬁcantly exceeded the activity of LF2000
(Figure 2a and Supplementary Figure S1a). At an siRNA
concentration as low as 6nM, signiﬁcant RNAi responses
were observed in both cell-lines and at higher siRNA con-
centrations, >90% gene silencing was obtained using PF6.
The concentration of siRNA needed to knock down 50%
of the target gene (i.e. IC50) was ranging from 2.8 to
8.9nM in commonly used adherent cell-lines including
HEK, HeLa, U2OS, CHO, RD4, Hepa1c1c7 and Bhk21
cells (Supplementary Table S2). Importantly, the observed
knockdown was siRNA-mediated and not imparted by
the peptide, since 100nM control siRNA formulated
with PF6 (i.e. Ctrl) had no impact on gene expression.
In keeping with previous studies, we rarely obtained
>75% silencing using LF2000, even at 50nM siRNA con-
centrations. By increasing the amount of liposomes, it was
possible to obtain near 90% RNAi responses, however,
this concomitantly resulted in severe cellular toxicity
(data not shown). To fully validate the potential of PF6,
another reagent, optimized for siRNA transfections, was
included for comparison, namely Lipofectamine
TM
RNAiMAX (RNAiMAX). In the more refractory
HepG2 hepatoma cell-line, we observed the same trend
as in the other cell types, with PF6 being the most
potent vector, and no signiﬁcant differences were
observed between LF2000 and RNAiMAX (Figure 2b
and Supplementary Figure S1b).
Many transfection systems are strictly dependent on
deﬁned amounts of reagents in order to efﬁciently trans-
fect cells. In order to address whether this applies also for
PF6-mediated delivery, a dose-titration of PF6 was carried
out and compared with both LF2000 and RNAiMAX.
For PF6, we started at MR40 (i.e. the amount used in
all other experiments in serum containing media) and
titrated the concentration of PF6 down to MR10,
keeping the siRNA amount constant. The same was
done with the two lipid-based vectors. Interestingly, with
PF6, as opposed to LF2000, the relative amount of
peptide over siRNA could be varied, still leading to sig-
niﬁcant RNAi responses (Supplementary Figure S2a, left
panel). Although essentially full silencing was observed
using molar ratio 40 (MR40) and 50nM siRNA, >80%
silencing was observed using MR10 in different types of
cells (Supplementary Figure S2a, right panel). Moreover,
in contrast to both LF2000 and RNAiMAX, that are
dependent on relatively low cell conﬂuence for their per-
formance, we observed only small variations in PF6/
siRNA-mediated RNAi responses when varying cell
densities (Figure 2c and Supplementary Figure S2b).
After quantitatively determining the magnitude of gene
silencing, we addressed the percentage of cells undergoing
RNAi by using CHO cells stably expressing EGFP, and
monitoring expression after treatment with PF6/
EGFP-siRNA complexes by ﬂow cytometry and ﬂuores-
cence microscopy. By treating cells with 50nM PF6/
siRNA in the presence of serum, entire cell populations
underwent RNAi within 48h, as judged by the complete
shift in the FACS histograms as well as the lack of
EGFP-positive cells under the microscope (Figure 2d
and Supplementary Figure S2c). In contrast, a large
fraction of the target population was not silenced by
lipofection, using 100nM siRNA. Another important
aspect for successful implementation of RNAi is the
persistence of gene silencing over time. After a single treat-
ment with PF6/siRNA in EGFP-CHO cells, signiﬁcant
gene silencing was observed for 5 days with slower
decay kinetics than with LF2000, using 50nM siRNA
(Figure 2e). Furthermore, repeating same treatments
every third day gave a complete RNAi response for at
least 8 days when using PF6/siRNA (Supplementary
Figure S2d).
Endogenous gene knockdown using PF6/siRNA
nanoparticles
After conﬁrming the potency of PF6 in commonly used
adherent cell-lines by reporter-gene silencing, we
investigatedthetargetingofanendogenousgene,hypoxan-
thine phosphoribosyltransferase 1 (HPRT1), by measuring
mRNA levels using qPCR. HPRT1 was chosen due to the
long cellular half-life of the protein ( 48h) and thereby
minimal impact on the vitality of the transfected cell and
limited off-target effects of the speciﬁc HPRT1 siRNA
sequence were expected (22). In order to accurately deter-
mine the degree of down-regulation, glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as an
internal standard for quantiﬁcation. Initially, the kinetics
of HPRT1 RNAi in human Hepa1c1c7 hepatoma cells was
assessed. Strikingly, already after 4h, >50% gene silencing
was observed and the magnitude of RNAi increased over
time with a 95% knock-down after 8h with PF6, using
50nM siRNA (Figure 3a). Silencing was much faster
than with lipofection (Figure 3a), in keeping with the
rapid endosomal release of siRNA when using PF6.
Next, primary mouse embryonal ﬁbroblasts (MEFs) were
3978 Nucleic Acids Research, 2011,Vol.39, No. 9used for screening of HPRT1 RNAi responses. Twenty-
four hours after siRNA treatment, dose-dependent RNAi
responses were observed using PF6 both in serum and
serum free media, exceeding the activity of lipofection,
with IC50 values of around 6nM (Figure 3b).
Thereafter, human umbilical vein endothelial cells
(Huvec) were assayed for RNAi. These cells are extremely
difﬁcult to transfect by chemical means, which limits their
utility for large scale RNAi-screens. Since LF2000 was
completely inactive in these cells, Transductin (i.e. Tat-
DRBD) served as a positive control, in addition to
RNAiMAX (Figure 3c). As expected, Transductin was
efﬁcient at transducing Huvec cells only when using high
siRNA concentrations (100–400nM) and when perform-
ing experiments under serum-free conditions. Using only
25nM siRNA, we obtained stronger RNAi response with
PF6 as compared to both Transductin and RNAiMAX at
100nM siRNA (Figure 3c). Similar results were obtained
in Jurkat T-lymphocyte cells. At 100nM siRNA, transfec-
tions in serum- and GAG-free media were comparable
between PF6 and transductin, but PF6 performed signiﬁ-
cantly better in serum-containing media (Figure 3d). A
complete list of cells and targets used for RNAi experi-
ments with corresponding IC50 values is found in
Supplementary Table S2.
Finally, we investigated the possibility to target primary
mouse embryonal stem (mES) cells using PF6, since these
are very useful for modeling and understanding
progression of disease but very difﬁcult to transfect
without inducing cellular differentiation. Freshly
prepared mES-cells were subjected to siRNA treatment
and a dose-dependent RNAi response was observed at
24h after using PF6/siRNA particles, again exceeding the
activity of the other reagents (Figure 3e). In order to
conﬁrm that cellular pluripotency was intact following
PF6/siRNA treatment, expression of the pluripotency
regulator Oct4 was assessed (23). Three days after treat-
ment with PF6/HPRT1-siRNA, the expression level of
Oct4 remained unaffected, with cells growing in sphere-
like colonies, indicating that PF6 has negligible effects on
cellular differentiation (Figure 4a). Accordingly, when
usingPF6/Oct4-siRNAweobservedasigniﬁcantreduction
in Oct4 expression levels after 24h (Figure 4b) and loss of
colonygrowth within 72h(Figure 4a), conﬁrming that PF6
per se does not affect the pluripotency of cells.
In vitro toxicity of PF6/siRNA nanoparticles
Next, cell viability studies were performed, using the
Wst-1 assay, in the most refractory cells. Although none
of the reagents reduced viability of ES or Jurkat cells, the
viability of Huvec cells was reduced substantially with
all reagents except for PF6/siRNA (Supplementary
Figure S3a–c). Furthermore, full-genome microarray
analysis was carried out to exclude potential off-target
transcriptome effects imparted by PF6. HeLa cells were
transfected with either PF6/siRNA or LF2000/siRNA and
(a)
(d)( e)
(b)( c)
Figure 2. PF6-mediated siRNA delivery into reporter cells. (a) RNAi response in luc-HEK cells at 24h after treatment with increasing concentration
of luc-siRNA using PF6 or LF2000. One hundred nanomolar EGFP siRNA complexed with PF6 (ctrl) and 50nM naked luc siRNA (Mock) was
used as controls. Luminescence (RLU) was normalized to protein content and data presented as expression relative to untreated cells.
(b) Dose-response in HepG2 cells after treatment as in (a). (c) Impact of cell conﬂuence. Luc-U2OS cells seeded at indicated densities 1day prior
experiment were treated and analyzed as in (a) using 50nM siRNA with PF6, LF2000 or RNAiMAX. (d) Flow cytometry histogram analysis of
EGFP RNAi response in EGFP-CHO cells at 48h post treatment with 100nM free EGFP siRNA (mock) or complexed with LF2000 or PF6.
(e) Flow cytometry analysis of EGFP knockdown decay kinetics following single treatment with siRNA. Treatments and subsequent analysis were
performed as is in (d) but using 50nM siRNA. Mock depicts only siRNA and Ctrl corresponds to 50nM PF6/luc-siRNA. All experiments were
performed at least three times in duplicate, showing the standard error of the mean (SEM).
Nucleic Acids Research,2011, Vol.39, No. 9 3979mRNA was analyzed at 24h post treatment using a
1.6-fold increase/decrease ﬁlter to assess alterations.
Noticeably, expression of more than 10 transcripts was
signiﬁcantly altered by LF2000 treatment whereas only
one was affected by PF6 in addition to the HPRT1
target (Figure 5a). Naked siRNA had no signiﬁcant
impact on the transcriptome (data not shown). However,
since overall mRNA and protein levels do not necessarily
correlate (24), mass spectrometry-based proteomics was
carried out. The expression of 18 proteins was signiﬁcantly
altered upon transfection with LF2000 compared to
12 proteins only in PF6 samples out of 2347 proteins
identiﬁed (Figure 5b). Considering the scale of proteome
coverage the number of deregulated proteins is very low.
Similar results were obtained using a non-targeting
EGFP-siRNA although the number of off-target
proteins was signiﬁcantly higher. Out of 4212 proteins
identiﬁed and quantiﬁed, 140 proteins were de-regulated
with PF6 and more than 300 with RNAiMAX, with
several proteins overlapping (Figure 5c). These
(a)
(c)( d)( e)
(b)
Figure 3. PF6-mediated siRNA delivery into refractory cells. (a) HPRT1 mRNA knockdown kinetics in Hepa1c1c7 cells following treatment with
PF6, LF2000 or RNAiMAX in complex with 50nM siRNA. Values represent mean normalized to GAPDH mRNA and presented as percent of
untreated cells. qPCR analysis of HPRT1 mRNA levels at 24 h post treatment of (b) primary MEF cells, (c) Huvec cells, (d) Jurkat cells or (e)
mES-cells with HPRT1-siRNA using PF6, LF2000, RNAiMAX or Transductin as indicated. One hundred nanomolar luc-siRNA complexed with
PF6 (Ctrl) and 100nM naked HPRT1-siRNA (mock) were used as controls. Key applies to b–e.
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Figure 4. PF6/siRNA delivery into mES cells. (a) Fluorescence microscopy analysis of Oct4 expression and genomic staining (DAPI) in mES cells
72h after treatment with PF6/HPRT1-siRNA, PF6/Oct4-siRNA and Oct4-siRNA only (mock). Ctrl depicts cells without primary antibody. (b) Oct4
RNAi response measured by qPCR 24h after treatment with 50nM PF6/Oct4-siRNA or PF6/HPRT1-siRNA. GAPDH was used as internal
standard.
3980 Nucleic Acids Research, 2011,Vol.39, No. 9discrepancies between the two siRNAs could be explained
by the fact that HPRT1 siRNA has been optimized to
reduce off-targeting in contrast to EGFP-siRNA.These
results clearly show that PF6 displays lower cytotoxicity
than commonly used lipid-based reagents.
Inﬂammation responses of PF6/siRNA in vitro and in vivo
After conﬁrming the potency of PF6 in various cell
cultures, we next sought to evaluate whether this
compound could be applied for systemic delivery of
siRNA in mice. An important parameter for in vivo
delivery of siRNAs is to avoid triggering inﬂammatory
responses (25). This was assessed in transformed human
monocytic THP1 cells, where PF6 had negligible effects
on the release of tumor necrosis factor (TNF)-a and inter-
leukin (IL)-1b as compared to the positive control lipo-
polysaccharide (LPS) after 4 and 24h treatments
(Supplementary Figure S3d). These results were further
corroborated in vivo where negligible induction of the
inﬂammatory mediator IL-6 was observed 24h after
systemic administration of 1mg/kg PF6/siRNA
(Figure 6a). Also, TNF-a was not detected (data not
shown) and the number of white blood cells as well as
the level of C-reactive protein remained unchanged
(Table 1), again indicating minimal inﬂammatory
responses.
Systemic delivery of PF6/siRNA nanoparticles
The lack of inﬂammatory responses in combination with
the efﬁcient RNAi responses observed in cell culture
encouraged us to further investigate the potential of PF6
for systemic delivery of siRNA. We chose to target
HPRT1, since it is abundant in all tissues and the
siRNA has been carefully optimized to minimize
off-target effects. PF6 was formulated with HPRT1-
siRNA or with control siRNA in water in half of the in-
jection volume (i.e. 100ml) at MR30. After 30min, 100ml
of 10% mannitol solution was added to the complexes.
HPRT1-siRNA was formulated with PF6 at doses
ranging from 0.25 to 1mg/kg siRNA and administered
i.v. into mice. After 24 h, only modest gene silencing
was observed in different organs at the highest dose
(data not shown). Given that the highest silencing in cell
cultures was observed at 48h, additional treatments were
carried out measuring HPRT1 silencing at 72 h using a
1mg/kg dose. Whereas control treated animals displayed
PF6/siRNA protein ratio LF2000/siRNA protein ratio
0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5
0.01%
0.1%
1.0%
10.0%
30.0%
50.0%
70.0%
90.0%
99.9%
99.99%
99.0%
0.01%
0.1%
1.0%
10.0%
30.0%
50.0%
70.0%
90.0%
99.9%
99.99%
99.0%
C
u
m
u
l
a
t
i
v
e
 
d
i
s
t
r
i
b
u
t
i
o
n
C
u
m
u
l
a
t
i
v
e
 
d
i
s
t
r
i
b
u
t
i
o
n
RNAiMAX/siRNA
Total deregulated
proteins: 307 of 4212
PF6/siRNA
Total deregulated
proteins: 140 of 4212
Overlapping deregulated
proteins: 96 of 4212
211 96 44
(a)
(b)( c)
Figure 5. Analysis of the transcriptome and proteome after PF6/siRNA treatment. (a) Full-genome microarray analysis proﬁle after 24h of HeLa
cells treated with PF6 or LF2000 complexed with 50nM HPRT1-siRNA. Red line indicates a 1.6-fold increase/decrease and blue and red dots
indicate genes with signiﬁcantly altered expression compared to untreated cells. (b) Mass-spectrometry based proteomic analysis of HeLa cells after
treatment with 100nM siRNA in serum-supplemented media either using PF6 or LF2000. Results were normalized to treatments with only siRNA
and presented as normal probability plot with a 99% conﬁdence limit. (c) Mass-spectrometry based proteomic analysis of HeLa cells after treatment
with 100nM EGFP-siRNA in serum-supplemented media either using PF6 or RNAiMAX. Results were normalized to treatments with only siRNA
and presented as Venn diagram displaying the deregulated proteins with each reagent.
Nucleic Acids Research,2011, Vol.39, No. 9 3981no alterations in HPRT1 levels, PF6/siRNA-treated
animals had signiﬁcantly reduced expression of HPRT1
in kidneys (Figure 6b). RNAi responses were also
observed in other tissues than kidney with the most prom-
inent effects in liver and lungs (Figure 6c).
Importantly, these treatments were not associated with
any acute toxicity according to the body weight loss cal-
culations after 72h (Supplementary Figure S3e). Although
PF6/HPRT1 siRNA treatment reduced the body-weight,
this is likely a result of HPRT1 knockdown, since PF6/
luc-siRNA had no impact on the weight. Accordingly,
liver transaminase levels (ALT/AST) remained at the
levels of vehicle-treated mice 72 h post treatment with
1mg/kg of PF6/luc-siRNA (Figure 6d), suggesting negli-
gible effects on liver function. Similarly, serum creatinine
levels were unaffected by the same treatment, thus con-
ﬁrming intact kidney function (Figure 6d). These results
were supported by histopathological examinations of
tissue sections where liver, kidney and lung histology
appeared normal with no signs of acute toxicity
(Figure 6e). A list of examined clinical chemistry and
hematology parameters is given in Table 1.
To further validate the potency of PF6 in vivo, an add-
itional mouse model was utilized. Mice expressing
luciferase in the liver were treated with 0.2 or 1mg/kg of
PF6/luc-siRNA and assayed over 15 days by means of full
body in vivo bioluminescence imaging (Figure 7 a and b).
While naked luc-siRNA was unable to induce an RNAi
response, PF6/siRNA-treated animals displayed reduced
expression of luciferase for 2 weeks, reaching 75%
silencing at day 5, when using the 1mg/kg dose
(Figure 7a). Even at a dose as low as 0.2mg/kg, 50%
gene silencing was observed when using PF6 (Figure 7b).
Furthermore, i.v.-injected PF6/siRNA nanoparticles and
naked siRNA administered via hydrodynamic injection
produced the same RNAi effect, reducing luciferase
0
25
50
75
100
125
H
P
R
T
1
 
m
R
N
A
 
l
e
v
e
l
s
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
)
Vehicle
Mock
Ctrl
PF6/HPRT1-
siRNA
Vehicle siRNA PF6/siRNA
0
25
50
75
100
125
150
2
4
6
8
10 ALT
AST
Creatinine
A
L
T
/
A
S
T
 
(
U
/
L
)
C
r
e
a
t
i
n
i
n
e
 
(
m
m
o
l
/
L
)
r e v i L g n u L y e n d i K
(a)
(d)( e)
(b)( c)
I
L
-
6
 
(
p
g
/
m
l
)
0
25
50
75
100
125
H
P
R
T
1
 
m
R
N
A
 
l
e
v
e
l
s
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
)
Kidney
Brain
Lung
Spleen
Liver
Heart
Figure 6. PF6-mediated siRNA delivery in vivo.( a) Analysis of IL-6 serum levels by ELISA 24 h following i.v. administration of 1mg/kg of naked
siRNA, PF6/siRNA formulated in 5% glucose or glucose only (vehicle). LPS (10mg) was used as positive control (n=5 for each group). (b) HPRT1
knockdown in kidney at 72h post i.v. treatment with 1mg/kg of PF6/HPRT1-siRNA. Vehicle (5.4% mannitol), naked siRNA (mock) and 1mg/kg of
PF6/luc-siRNA (Ctrl) were used as controls. Organs were lysed, mRNA extracted and HPRT1 mRNA measured by qPCR. These are mean values of
HPRT1 normalized to GAPDH mRNA and presented as percent of untreated animals. Error bars indicate SEM, n=3–6 for each group. (c) HPRT1
RNAi response in indicated organs 72h after systemic delivery of 1mg/kg PF6/HPRT1-siRNA formulated in 5.4% mannitol. Organs were lysed,
mRNA extracted and HPRT1 mRNA measured by qPCR. These are mean values of HPRT1 normalized to GAPDH mRNA and presented as
percent of untreated animals. Error bars indicate SEM, n=3–6 for each group. (d) Transaminase (ALT/AST) and creatinine serum levels at 72 h
after treatment as in (a) (n=5 for each group) and corresponding histopathology analysis of hematoxylin–eosin stained tissue sections (kidney, lung
and liver) from mice treated with 1mg/kg PF6/siRNA (e). Except for (a), all in vivo formulations were administered in 5.4% mannitol solution.
Table 1. Clinical chemistry and hematology parameters for PF6/siRNA treated mice
Treatment group Spleen weight (mg) Creatinine (mmol/l) ALT (U/l) AST (U/l) RBC ( 10
12/l) WBC ( 10
9/l) CRP (mg/l)
Vehicle 109.0±8.0 6.5±0.5 33.9±5.1 100.4±0.2 8.9±0.4 5.0±0.8 0.06±0.01
siRNA 91.6±5.2 8.6±1.1 33.6±3.3 118.3±9.1 9.3±0.3 4.7±0.6 ND
PF6/siRNA 113.7±9.8 8.0±0.8 30.7±2.1 92.3±7.3 8.6±0.5 4.3±0.7 0.09±0.02
ALT, alanine transaminases; AST, aspartate transaminases; RBC, red blood cells; WBC, white blood cells; CRP, C-reactive proteins.
3982 Nucleic Acids Research, 2011,Vol.39, No. 9expression in the liver at comparable levels (Figure 7c).
This is extremely encouraging, since hydrodynamic injec-
tion is considered one of the most efﬁcient means of
transducing liver (26). Collectively, the results illustrate
the non-toxic nature and high potency of PF6 for
systemic siRNA delivery.
DISCUSSION
Modulation of gene expression using RNAi technology
has received immense attention in recent years.
However, the anionic nature and large size of siRNAs
unfortunately imply that the cell membrane constitutes
an impermeable barrier that impedes harnessing the full
potential of this technology. Thus, the key challenge in the
RNAi ﬁeld is to efﬁciently deliver siRNA molecules into
the cytoplasm of cells. In the past we have had great
success with one particular peptide, TP10, in the delivery
of a wide array of cargoes, and we therefore iteratively
modiﬁed this peptide to render it an efﬁcient siRNA
delivery vehicle. Our design aimed to solve two often
occurring problems: (i) endosomal entrapment of
material following endocytosis and (ii) the instability of
CPPs in serum-containing environment. We hypothesized
that incorporation of CQ analogues into CPP backbone
would mimic the pH buffering and osmotic endosome
swelling effects of CQ (27). Hence, we introduced four
novel triﬂuoromethylquinoline-based derivatives (QN)
via a succinylated lysine tree into the peptide sequence
to improve endosomal release of siRNA and, secondly, a
stearic acid moiety was attached to the N-terminus of
TP10 to increase the serum stability of the peptide.
Different groups, including ourselves, have previously
shown that CPPs can form particles with negatively
charged ONs (including siRNAs) with a diameter of
100–300nm (9,28).
Indeed, by simply mixing PF6 with siRNA in water,
stable nanoparticles are formed within minutes which
remain stable for weeks. This is a clear advantage
compared to other efﬁcient in vivo siRNA delivery
systems that require complicated particle formation pro-
cedures (10,29,30). The mean diameter of PF6/siRNA
nanoparticles, formed at various MRs, remains well
below 200nm similarly to other efﬁcient siRNA nano-
particle formulations. In contrast to previous studies
using MPG-peptide derivatives (9,28), we did not
observe any particle aggregation at the higher MRs,
instead, particles were slightly smaller in size and more
homogenous. Moreover, particle size remained in this
range also in the presence of serum, where water-formed
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Figure 7. Assessment of PF6-mediated siRNA delivery in vivo using a bioluminescence model. (a) In vivo bioluminescence imaging of luciferase
expression following i.v. delivery of 1mg/kg of luc-siRNA, with or without PF6, at Day 3 and 5 post injection in animals with expression of luc from
liver. (b) Luc knockdown over time after treatments with 0.2 or 1mg/kg of PF6/luc-siRNA or 1mg/kg naked luc-siRNA (mock). (c) Luc knockdown
over time after treatments with 1mg/kg luc-siRNA using hydrodynamic injection (HI) or 1mg/kg of PF6/luc-siRNA. Naked luc-siRNA (mock)
(1mg/kg) was used as control. At least four animals were included in each treatment group. All in vivo formulations were administered in 5.4%
mannitol solution.
Nucleic Acids Research,2011, Vol.39, No. 9 3983particles often aggregate. Thus the particles should be
suitably sized for in vivo conditions (9–11,31). To our
knowledge, this is the ﬁrst time the size of CPP/siRNA
complexes have been analyzed by DLS in the presence of
serum and these results suggest that PF6/siRNA particles
are extremely stable. Interestingly, the PF6/siRNA
nanoparticles are even more stabilized in mannitol and
glucose, which are commonly utilized excipients for
in vivo formulations.
After conﬁrming the formation of stable, nano-sized
particles, we next validated the endosomolytic design of
the peptide. Although some CPPs (e.g. MPG derivatives)
have been reported to work by direct translocation, most
other CPPs in complex with cargo are evidently
endocytosed (32). For example, we have previously
shown that the endocytic pathway is determined by the
chemical nature of the peptide. While purely cationic
CPPs are macropinocytosed, amphipathic peptides, such
as TP10, utilize classical clathrin-mediated endocytosis for
internalization (33). Common for all studies showing
endocytic uptake of CPPs is that co-addition of CQ dras-
tically increases the biological activity of the delivered
cargo, emphasizing that endosomal sequestration is a
main limiting factor for most CPPs. In line with most
other CPPs, when associated with cargo, we here
conﬁrm that PF6/siRNA nanoparticles are internalized
via endocytosis, judged by the extensive vesicular distribu-
tion observed by ﬂuorescence microscopy. To assess the
endosomolytic properties of the QN-conjugated PF6, it
was compared to PF3, which lacks the modiﬁcation.
Both peptides displayed similar uptake but only PF6
was able to promote siRNA-mediated RNAi. The
greater ability of PF6 to promote endosomal escape was
further supported by the fact that co-addition of free CQ
in solution increased PF3/siRNA-mediated RNAi signiﬁ-
cantly while the same treatment had no impact on
PF6-mediated siRNA delivery. This was conﬁrmed in
the liposomal leakage model where, at endosomal pH,
PF6 had signiﬁcantly higher destabilizing capacity of lipo-
somes than PF3, and by the rapid PF6-mediated RNAi
kinetics. These results clearly illustrate the pH-dependent
endosomolytic properties of PF6, which enable fast release
of siRNA into the cytoplasm.
The endosomolytic design rendered PF6 highly efﬁcient
in promoting siRNA-mediated RNAi in various cells, tar-
geting either reporter genes (EGFP and luciferase) or
endogenous genes (HPRT1 and Oct-4). In contrast to
lipofection, PF6 promoted siRNA-mediated gene
silencing in entire cell populations and, thus, dose-
dependently exceeded the activity of the commercial
lipofection reagents in practically all tested cells. Most
importantly, the activity was well preserved in serum.
Furthermore, while primary cells and suspension cells
remain relatively refractory to most transfection
strategies, PF6 efﬁciently promoted siRNA-mediated,
dose-dependent gene silencing in different refractory cells
such as Huvec, Jurkat, C17.2 neuronal stem cells and
ES-cells with IC50 values ranging from 10 to 50nM.
These results collectively show that PF6 has the potential
to transfect different cell types without affecting the
phenotype of cells, which opens new possibilities for
large-scale RNAi screens in disease-relevant primary
cells. Furthermore, many siRNA transfection systems,
such as lipofection, are strictly dependent on deﬁned
amounts of reagents and certain cell densities to be efﬁ-
cient. Thus, small variations in lipid amount or cell con-
ﬂuence might drastically affect their performance. In
contrast, the exact molar ratio between siRNA and PF6
as well as the cell density could be varied, retaining the
RNAi effect. These are clear advantages when PF6 is
compared to other peptide- and cationic lipid-based
vectors (9,10) because this allows optimizing transfection
conditions when working with sensitive cell-lines. Also,
being insensitive to varying cell conﬂuence is very import-
ant for in vitro screens that require different end-points,
and for successful in vivo implementation, where the target
is intact tissues.
It is well-established that high transfection levels are
commonly associated with signiﬁcant cellular toxicity.
For example, lipofection typically displays a linear correl-
ation between efﬁciency and toxicity. At the recommended
dosing, both LF2000 and RNAiMAX display only minor,
non-signiﬁcant, cytotoxicity but the achieved siRNA-
mediated knockdown is unfortunately not complete. By
increasing the lipid amount in siRNA experiments,
RNAi responses of 85% can be achieved in regular
adherent cells but the viability of cells concomitantly
decreases drastically. Therefore, when screening for
novel siRNA-delivery vectors it is pivotal to both
analyze knockdown levels and to account for potential
long-term toxicity. A major reason for the increased
interest in CPPs in recent years is that they are considered
to be relatively non-toxic for cells. However, it has been
previously reported that CPP-related toxicities can occur
at high peptide concentrations, especially when using
amphipathic peptides such as TP10 (34,35). Thus, we
investigated the potential toxicity of PF6. As judged by
the Wst-1 assay as well as microarray and proteomics
data, PF6 delivers siRNA to its target cells in a
non-toxic manner.
After conﬁrming the potency of PF6 in cell culture, we
next assessed the suitability of the vector for systemic
delivery of siRNA in mice. Using the HPRT1 house-
keeping gene as a target, we observed pronounced
knockdown in liver, kidney and lung, following systemic
delivery of PF6/HPRT1-siRNA, possibly reﬂecting their
high blood supply. The majority of previous other success-
ful RNAi reports are indeed based on results achieved
from the liver, whereas efﬁcient gene knockdown in
other organs requires much more complicated strategies
and multicomponent delivery vectors (29,30). Strikingly,
we observed >60% gene silencing also in kidneys and
lung, by using PF6 as a single-component vehicle
without additional targeting motifs. To corroborate the
applicability of PF6 for in vivo delivery we could exclude
most of the general toxic and immunogenic side-effects.
Obviously, an important parameter for in vivo delivery of
siRNAs is to avoid triggering inﬂammatory responses
(25). Naked siRNAs are known to frequently stimulate
inﬂammatory responses (36–39). Thus, an optimal vector
should shield the siRNA through the endo-lysosomal
pathways, where most TLRs are located and concurrently
3984 Nucleic Acids Research, 2011,Vol.39, No. 9not be immunogenic per se. PF6 effectively shielded the
delivered siRNA from TLRs, suggested by the negligible
immunogenic response, both in vitro and in vivo.
Histopathological examination did not show any signs
of toxicity in liver, lung or kidneys, and several other
tested clinical or hematological parameters remained un-
affected. This contrasts to many other polycationic vectors
that have been exploited in vivo where, in particular,
kidney and lung toxicity has been reported (40,41).
Based on the encouraging results of strong RNAi
response in liver we utilized another animal model to
analyze gene silencing in liver only. In this model, mice
with luciferase expressed in the liver were treated with
PF6/luc-siRNA nanoparticles. By using doses up to
1mg/kg, substantial luciferase knockdown was observed,
which lasted for more than a week. Hydrodynamic injec-
tion is frequently considered the golden standard tech-
nique for achieving siRNA-mediated RNAi responses in
liver (42). Intriguingly, RNAi responses with PF6/siRNA
in liver were at least in line with that standard technique.
These results are comparable to recently published results
on the use of lipid nanoparticles (LNPs) for siRNA, tar-
geting luciferase in liver of mice (43). Using LNPs with
optimized composition (right amount of cationic lipo-
somes, polyethylene glycol and cholesterol), the authors
reported on signiﬁcant RNAi responses for 10 days
using doses of 3mg/kg siRNA. The strong RNAi re-
sponses observed in liver could relate to the negative
zeta-potential observed for PF6/siRNA in serum media
since it has been previously reported that various
lipid-based systems with negative surface charge efﬁciently
target hepatic cells in vivo (44,45). Although stronger gene
silencing in the liver has been reported at lower siRNA
doses with cholesterol-functionalized and other
lipid-based delivery systems, e.g. SNALP and lipidoids,
these vehicles contain multiple components and require
additional formulation procedures. The PF6-platform,
however, works as a one-component system without any
targeting motifs and it does not require cumbersome for-
mulation procedures for being active. Also, we have
utilized siRNAs composed of unmodiﬁed RNA, whereas
in other studies different modiﬁcations have been ex-
ploited, which render siRNAs more stable against enzym-
atic degradation in the systemic circulation. Thus, there is
room for improvement and by using stabilized siRNAs in
combination with optimized formulations, the PF6/
siRNA nanoparticles are likely to work at signiﬁcantly
lower doses.
Our results collectively demonstrate that PF6 has the
desired in vitro properties of a promising transfection
agent in that it promotes siRNA delivery to entire cell
populations, is highly active in hard-to-transfect cells, is
relatively tolerant to serum, and is essentially independent
of cell conﬂuence. Furthermore, PF6 displays very low
toxicity according to microarray and proteomics
analysis. Most importantly, the vector/siRNA complexes
are suitable for systemic delivery without any observed
toxicity, which implies that, in addition to having signiﬁ-
cant utility for RNAi screens in vitro, it has therapeutic
potential.
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